Clinical trial
IFM 99-02 Thalidomide in Myeloma
NCT00222053 · University Hospital, Toulouse, Other · Completed
Key facts
| NCT number | NCT00222053 |
|---|---|
| Title | IFM 99-02 Thalidomide in Myeloma |
| Lead sponsor | University Hospital, Toulouse, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Thalidomide, Biphosphonates |
| Enrollment | 800 |
| Start date | Apr 1, 2000 |
| Primary completion | Sep 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 2, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: